Multiple myeloma is a devastating and incurable disease affecting thousands of Australians and their families. Patients endure months or even years of debilitating treatment, accompanied by an immense physical, psychological and financial toll.

This white paper analyses the current state of chimeric antigen receptor (CAR) T-cell therapy in Australia, expected opportunities and our healthcare system’s preparedness for delivering CAR T-cell therapy at scale. It also provides results of a rigorous evidence-based economic analysis of the health and societal benefits of CAR T-cell therapy.

There are seven evidence-based recommendations to ensure Australia’s healthcare system is ready, willing and able to implement CAR T-cell therapy at scale within the next five years. There is a window of opportunity to change the future for Australians living with, and dying from, blood cancer - including multiple myeloma. Embracing these recommendations will ensure patients in need receive equitable and timely access to lifesaving therapies, positioning Australia as a leader in care.